These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 37894850)

  • 41. JAK2-STAT Epigenetically Regulates Tolerized Genes in Monocytes in the First Encounter With Gram-Negative Bacterial Endotoxins in Sepsis.
    Morante-Palacios O; Lorente-Sorolla C; Ciudad L; Calafell-Segura J; Garcia-Gomez A; Català-Moll F; Ruiz-Sanmartín A; Martínez-Gallo M; Ferrer R; Ruiz-Rodriguez JC; Álvarez-Errico D; Ballestar E
    Front Immunol; 2021; 12():734652. PubMed ID: 34867954
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dysregulated Interferon Response and Immune Hyperactivation in Severe COVID-19: Targeting STATs as a Novel Therapeutic Strategy.
    Eskandarian Boroujeni M; Sekrecka A; Antonczyk A; Hassani S; Sekrecki M; Nowicka H; Lopacinska N; Olya A; Kluzek K; Wesoly J; Bluyssen HAR
    Front Immunol; 2022; 13():888897. PubMed ID: 35663932
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
    Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
    Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 45. SARS-CoV-2 spike protein binds to bacterial lipopolysaccharide and boosts proinflammatory activity.
    Petruk G; Puthia M; Petrlova J; Samsudin F; Strömdahl AC; Cerps S; Uller L; Kjellström S; Bond PJ; Schmidtchen AA
    J Mol Cell Biol; 2020 Oct; 12(12):916-932. PubMed ID: 33295606
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Endotoxin tolerance and low activation of TLR-4/NF-κB axis in monocytes of COVID-19 patients.
    Dorneles GP; Teixeira PC; Peres A; Rodrigues Júnior LC; da Fonseca SG; Monteiro MC; Eller S; Oliveira TF; Wendland EM; Romão PRT
    J Mol Med (Berl); 2023 Feb; 101(1-2):183-195. PubMed ID: 36790534
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lidocaine reinforces the anti-inflammatory action of dexamethasone on myeloid and epithelial cells activated by inflammatory cytokines or SARS-CoV-2 infection.
    Elizagaray ML; Mazitelli I; Pontoriero A; Baumeister E; Docena G; Raimondi C; Correger E; Rumbo M
    Biomed J; 2023 Feb; 46(1):81-92. PubMed ID: 35948250
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anti-inflammatory activity of a novel family of aryl ureas compounds in an endotoxin-induced airway epithelial cell injury model.
    Cabrera-Benitez NE; Pérez-Roth E; Casula M; Ramos-Nuez A; Ríos-Luci C; Rodríguez-Gallego C; Sologuren I; Jakubkiene V; Slutsky AS; Padrón JM; Villar J
    PLoS One; 2012; 7(11):e48468. PubMed ID: 23144889
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome.
    van de Veerdonk FL; Netea MG; van Deuren M; van der Meer JW; de Mast Q; Brüggemann RJ; van der Hoeven H
    Elife; 2020 Apr; 9():. PubMed ID: 32338605
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lipopolysaccharide Recognition in the Crossroads of TLR4 and Caspase-4/11 Mediated Inflammatory Pathways.
    Zamyatina A; Heine H
    Front Immunol; 2020; 11():585146. PubMed ID: 33329561
    [TBL] [Abstract][Full Text] [Related]  

  • 51. COVID-19 Sepsis: Pathogenesis and Endothelial Molecular Mechanisms Based on "Two-Path Unifying Theory" of Hemostasis and Endotheliopathy-Associated Vascular Microthrombotic Disease, and Proposed Therapeutic Approach with Antimicrothrombotic Therapy.
    Chang JC
    Vasc Health Risk Manag; 2021; 17():273-298. PubMed ID: 34103921
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Heparanase Blockade as a Novel Dual-Targeting Therapy for COVID-19.
    Xiang J; Lu M; Shi M; Cheng X; Kwakwa KA; Davis JL; Su X; Bakewell SJ; Zhang Y; Fontana F; Xu Y; Veis DJ; DiPersio JF; Ratner L; Sanderson RD; Noseda A; Mollah S; Li J; Weilbaecher KN
    J Virol; 2022 Apr; 96(7):e0005722. PubMed ID: 35319225
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synthetic anti-endotoxin peptides inhibit cytoplasmic LPS-mediated responses.
    Pfalzgraff A; Heinbockel L; Su Q; Brandenburg K; Weindl G
    Biochem Pharmacol; 2017 Sep; 140():64-72. PubMed ID: 28539262
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evidence for antibiotic-mediated endotoxin release as a contributing factor to lethality in experimental gram-negative sepsis.
    Morrison DC; Bucklin SE
    Scand J Infect Dis Suppl; 1996; 101():3-8. PubMed ID: 9060044
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis.
    Lin L; Tan B; Pantapalangkoor P; Ho T; Baquir B; Tomaras A; Montgomery JI; Reilly U; Barbacci EG; Hujer K; Bonomo RA; Fernandez L; Hancock RE; Adams MD; French SW; Buslon VS; Spellberg B
    mBio; 2012; 3(5):. PubMed ID: 23033474
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cytokine storm induced by SARS-CoV-2.
    Song P; Li W; Xie J; Hou Y; You C
    Clin Chim Acta; 2020 Oct; 509():280-287. PubMed ID: 32531256
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Changes and clinical significance of Toll-like receptor 2 and 4 expression in neonatal infections].
    Zhang JP; Chen C; Yang Y
    Zhonghua Er Ke Za Zhi; 2007 Feb; 45(2):130-3. PubMed ID: 17456342
    [TBL] [Abstract][Full Text] [Related]  

  • 58. SARS-CoV-2 pneumonia and bacterial pneumonia patients differ in a second hit immune response model.
    Moser D; Feuerecker M; Biere K; Han B; Hoerl M; Schelling G; Kaufmann I; Choukér A; Woehrle T
    Sci Rep; 2022 Sep; 12(1):15485. PubMed ID: 36109525
    [TBL] [Abstract][Full Text] [Related]  

  • 59. COVID-19: from the structure and replication cycle of SARS-CoV-2 to its disease symptoms and treatment.
    Zawilska JB; Lagodzinski A; Berezinska M
    J Physiol Pharmacol; 2021 Aug; 72(4):. PubMed ID: 34987123
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Monoclonal antibody therapy in COVID-19.
    Conti P; Pregliasco FE; Calvisi V; Caraffa Al; Gallenga CE; Kritas SK; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(2):423-427. PubMed ID: 33904269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.